Dai Xin Yue, Zi Ming Jie, Liu Chun Xiang, Wang Yi Ming, Gao Rui
Institute of Clinical Pharmacology of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Front Med (Lausanne). 2022 Nov 9;9:1025833. doi: 10.3389/fmed.2022.1025833. eCollection 2022.
Diabetic Foot (DF) is one of the most common complications of diabetes, and it is characterized by high morbidity, disability, lethality and low cure rate. Traditional Chinese medicine treatment has certain characteristics and advantages in diabetic foot. Due to selective reporting bias and heterogeneity of research results, on the one hand, relevant clinical studies are of low quality and poor practicability, and on the other hand, similar studies cannot be included in meta-analysis to form high-quality evidence-based evidence and evaluate the value of studies. Therefore, the development of a core set of outcomes (COS-TCM-DF) for traditional Chinese medicine for the treatment of diabetic foot is an important way to address these issues.
The COS-TCM-DF project will refer to the developed COS methodology and the steps are divided into four stages: (1) a scoping review and analysis of enrolled research protocols to collect and analyze all existing outcomes that have been used in trials on the prevention or treatment of diabetic foot with Chinese Medicine; (2) qualitative interviews with Diabetic foot patient and attendants to Collect additional outcomes related to them; (3) Gather opinionest and obtain initial consensus from key stakeholders, including patients, clinicians, researchers, and pharmaceutical company staff, through a Delphi survey; (4) a consensus meeting was held to develop the final COS-TCM-DF.
Currently, there is no COS on measuring or monitoring diabetic foot with TCM in trials or clinical practice. The COS-TCM-DF will be developed to advance the synthesis of evidence regarding the prevention and treatment of diabetic foot in TCM and to promote the standardized and consistent application of results in future studies in this field.
Registered with the Core Outcome Measures in Effectiveness Trials (COMET) database, December 2019 https://www.comet-initiative.org/Studies/Details/1553.
糖尿病足(DF)是糖尿病最常见的并发症之一,具有高发病率、高致残率、高致死率及低治愈率的特点。中医治疗糖尿病足具有一定特色和优势。由于研究结果存在选择性报告偏倚和异质性,一方面相关临床研究质量较低且实用性差,另一方面类似研究无法纳入荟萃分析以形成高质量循证证据并评估研究价值。因此,制定一套中医治疗糖尿病足的核心结局指标集(COS-TCM-DF)是解决这些问题的重要途径。
COS-TCM-DF项目将参考已制定的COS方法,步骤分为四个阶段:(1)对纳入的研究方案进行范围综述和分析,以收集和分析所有已用于中医预防或治疗糖尿病足试验的现有结局指标;(2)对糖尿病足患者及其陪护人员进行定性访谈,收集与之相关的其他结局指标;(3)通过德尔菲调查收集关键利益相关者(包括患者、临床医生、研究人员和制药公司员工)的意见并达成初步共识;(4)召开共识会议以制定最终的COS-TCM-DF。
目前,在试验或临床实践中尚无用于衡量或监测中医治疗糖尿病足的COS。COS-TCM-DF的制定将推动中医防治糖尿病足证据的综合,并促进该领域未来研究结果的标准化和一致性应用。
于2019年12月在有效性试验核心结局指标(COMET)数据库注册https://www.comet-initiative.org/Studies/Details/1553 。